Based on the mechanism of action of these HER2-targeted therapies, we hypothesized that the HER2 protein expression and stromal tumor-infiltrating lymphocyte (TIL) levels evaluated by immunohistochemistry (IHC) may predict the treatment response in HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.